AGENDA

Uniform Formulary Beneficiary Advisory Panel (UF BAP)
For the August 2024 Department of Defense Pharmacy and Therapeutics Committee Meeting
September 25, 2024 at 10:00 AM Eastern Daylight Time

Virtual Meeting

- **General session starts at 10:00 AM Eastern Daylight Time (Administrative meeting preceding)**

- **Roll Call**

- **Therapeutic Class Reviews**

  Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the Department of Defense (DoD) Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

  The DoD P&T Committee made recommendations for the following drugs/drug classes during the August 2024 meeting.

- **Drug Class Reviews**
  - *Leukemia and Lymphoma Agents: Bruton Tyrosine Kinase Inhibitors*
  - *Antilipidemic-1s Class*
    - *Statin Subclass*
    - *Non-statins and Combinations Subclass*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
  - *adalimumab (Cordavis Humira)—Targeted Immunomodulatory Biologics (TIBs): Tumor Necrosis Factor Inhibitors*
  - *adalimumab-ryvk (Simlandi)—TIBs: Tumor Necrosis Factor Inhibitors (TNFs)*
  - *danicopan (Voydeya)—Hematological Agents*
  - *diazepam (Libervant)—Anticonvulsants-Antimania Agents*
  - *elafibranor (Iqirvo)—Gastrointestinal-2 Agents*
  - *givinostat (Duvyzat)—Corticosteroids-Immune Modulators*
  - *macitentan/tadalafil (Opsynvi)—Pulmonary Arterial Hypertension*
  - *mavorixafor (Xolremdi)—Hematological Agents*
  - *mycophenolate mofetil (Myhibbin)—Immunosuppressives*

- *naloxone (Rextovy)—Alcohol Deterrents-Narcotic Antagonists: Narcotic Antagonists*
- *resmetirom (Rezdiffra)—Gastrointestinal-2 Agents*
- *sitagliptin/metformin (Zituvimet authorized generic)—Diabetes Non-Insulin: Dipeptidyl/Peptidase 4 (DPP-4) Inhibitors*
- *sotatercept-csrk (Winrevair)—Pulmonary Arterial Hypertension Agents*
- *spesolimab-sbzo (Spevigo)—TIBs: Miscellaneous Interleukins*
- *tocilizumab-aazg (Tyenne)—TIBs: Non-TNFs*
- *tovorafenib (Ojemda)—Oncological Agents*

➢ **Utilization Management Issues**

- **Prior Authorization (PA) Criteria—New Manual Prior Authorization (PA) Criteria**
  - *White Blood Cell Stimulants: eflapegrastim-xnst (Rolvedon)*
- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
  - *Endocrine Agents Miscellaneous: lanreotide 120 mg/0.5 mL syringe*
  - *Pain Agents —Topical Pain: lidocaine 5% patch (Tridacaine I, II, and III, Lidocan IV and V)*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
  - *Atopy: Oral JAK-1—upadacitinib (Rinvoq)*
  - *Atopy—benralizumab (Fasenra)*
  - *TIBs: Non-TNFs—vedolizumab (Entyvio)*
  - *TIBs: Non-TNFs—sarilumab (Kevzara)*
  - *Metabolic Agents Miscellaneous—maralixibat (Livmarli)*
- **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
  - *Corticosteroids-Immune Modulators: Adrenocorticotrophic Hormones corticotropin (Acthar Gel SelfJect)*
  - *Antiemetic-Antivertigo Agents—doxylamine/pyridoxine (Diclegis, Bonjesta)*
  - *Oncological Agents—trametinib (Mekinist), dabrafenib (Tafinlar), neratinib (Nerlynx), vemurafenib (Zelboraf), venetoclax(Venclexta), nilutamide (Nilandron), belzutifan (Welireg), tucatinib (Tukysa), glasdegib (Daurismo), erdafitinib (Balversa), and the Prostate Cancer drugs abiraterone (generic and Zytiga), enzalutamide (Xtandi), darolutamide, (Nubeqa), and apalutamide (Erleada)*
  - *TIBs: Non-TNFs—anakinra (Kineret)*

- *Sleep Disorders: Wakefulness Promoting Agents—solriamfetol (Sunosi)*
- *Sleep Disorders: Wakefulness Promoting Agents—pitolisant (Wakix)*
- *TIBs: TNFs— adalimumab (Humira)*
- *TIBs: Non-TNFs — secukinumab (Cosentyx)*
- *TIBs: Non-TNFs—tocilizumab (Actemra)*

- **Brand Over Generic PA Authorization and Tier 1 copay**
  - *Overactive Bladder Agents—mirabegron (Myrbetriq)*
  - *Anticonvulsant and Anti-Mania Agents—topiramate ER (Trokendi XR)*

- **PA Updates for Hepatitis C Virus Direct-Acting Antivirals Subclass**
  - *glecaprevir/pibrentasvir (Mavyret)*
  - *sofosbuvir/velpatasvir (Epclusa)*
  - *ledipasvir/sofosbuvir (Harvoni)*
  - *elbasvir/grazoprevir (Zepatier)*
  - *sofosbuvir (Sovaldi)*
  - *sofosbuvir/velpatasvir/voxilaprevir (Vosevi)*

- **Completely Excluded Drugs: Annual Review**

- **Panel Discussions**

  The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoD P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.